Compare JetBlue Airways Corporation (JBLU) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
JetBlue Airways Corporation vs Sana Biotechnology Inc — how do they compare? JetBlue Airways Corporation trades at $3.85 (market cap $1.48B), while Sana Biotechnology Inc trades at $2.85 (market cap $836.71M). The key difference: JetBlue Airways Corporation is the larger of the two by market cap, and JetBlue Airways Corporation is more actively traded (30,275,693 versus 4,507,444). Which is the better fit depends on your goals.
| JBLU | SANA | |
|---|---|---|
Market Cap | $1.48B | $836.71M |
Volume | 30,275,693 | 4,507,444 |
Sector | Industrials | Health |
52-Week High | $6.46 | $5.92 |
52-Week Low | $3.92 | $2.68 |
Typical Hold Time | 44 Days | — |
Enterprise Value | $8.84B | $749.96M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
JetBlue (JBLU) trades at $3.86, down 2.77% today, reflecting persistent bearish technical signals and weak earnings. The company reported a net loss of $602 million in 2025, with negative profit margins and declining revenue. Recent news includes route expansion to Colombia but also reduced capacity guidance due to weather and fuel costs. Technical indicators are bearish, with the stock trading near support levels.
The outlook remains challenging with high debt levels and consistent losses. Analyst consensus is mixed but leans hold, with a $5.89 price target suggesting potential upside if operational improvements materialize. Key risks include elevated fuel prices, competitive pressure, and macroeconomic sensitivity. Investment appeal is limited to speculative recovery bets amid ongoing fundamental headwinds.
SANA Biotechnology trades at $2.83, up 4.04% today, but faces significant fundamental challenges with negative revenue, substantial losses, and bearish technical indicators. The company reported a net loss of $244.17 million in 2025 with no revenue generation, while technical analysis shows a bearish trend with moving averages and ADX indicators signaling selling pressure. Recent investor conference presentations highlight ongoing business development activities.
Despite 82% analyst buy ratings and a $9.50 consensus price target, SANA carries high risk due to pre-revenue status, negative cash flow, and shareholder litigation concerns. The stock's investment case hinges on successful clinical development and future commercialization of its engineered cell therapies, requiring careful risk assessment by investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About JetBlue Airways Corporation
JetBlue Airways Corp is a low-cost airline that offers high-quality service, including assigned seating and in-flight entertainment. It carries over millions of customers with an average of more than 1,000 daily flights and served approximately 99 destinations in the United States, the Caribbean, and Latin America. The company currently operates Airbus A321, Airbus A320, and Embraer E190 aircraft types.
Read more on JBLU →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
